Table 7.
Clinical features of primary myelofibrosis patients experiencing and not experiencing thrombotic events
| Variable | With TE (n = 4) | Without TE (n = 26) | p value |
|---|---|---|---|
| Age, yr | 77.0 ± 3.3 | 63.1 ± 12.6 | 0.039 |
| Male sex | 3 (75.0) | 17 (65.4) | 0.704 |
| Palpable splenomegaly | 0 | 14 (53.8) | 0.044 |
| Laboratory findings | |||
| WBC, × 109/L | 10.8 ± 6.0 | 13.8 ± 11.6 | 0.626 |
| Monocytes, × 109/L | 1.2 ± 1.3 | 0.9 ± 0.7 | 0.513 |
| Hemoglobin, g/dL | 10.0 ± 1.4 | 10.3 ± 2.7 | 0.831 |
| Platelets, × 109/L | 784.8 ± 565.8 | 357.5 ± 246.4 | 0.012 |
| LDH, × UNL | 1.5 ± 0.2 | 2.2 ± 1.7 | 0.463 |
| Driver gene mutation | |||
| JAK2V617F | 3/4 (75.0) | 11/18 (61.1) | 0.362 |
| CALR | 0/4 (0.0) | 5/18 (27.8) | 0.562 |
| IPSS | 0.543 | ||
| Low | 0 | 5 (19.2) | |
| Intermediate-1 | 2 (50.0) | 6 (23.1) | |
| Intermediate-2 | 2 (50.0) | 9 (34.6) | |
| High | 0 | 6 (23.1) | |
| Comorbidity | |||
| Hypertension | 3 (75.0) | 7 (26.9) | 0.058 |
| Diabetes mellitus | 1 (25.0) | 6 (23.1) | 0.933 |
| Chronic kidney disease | 0 | 3 (11.5) | 0.474 |
| Smoking | 0 | 3 (11.5) | 0.474 |
| Hemorrhagic event | 0 | 1 (3.8) | 0.867 |
| Follow-up duration, yr | 2.4 ± 2.2 | 4.5 ± 4. 4 | 0.365 |
Values are presented as mean ± SD or number (%).
TE, thrombotic event; WBC, white blood cell; LDH, lactate dehydrogenase; UNL, upper normal limit; JAK2, Janus kinase 2; CALR, calreticulin; IPSS, International Prognostic Scoring System.